Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer

US10022444B2 · kind B2 · utility

Assignees

• Ganymed Pharmaceuticals GmbH · DE
• TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz · DE

Inventors

• Ugur Sahin · Mainz, DE
• Ozlem Tureci · Homburg, DE
• Rita Mitnacht-Kraus · Friedberg, DE
• Stefan Jacobs · Mainz, DE
• Magdalena Jadwiga Utsch · Uhlerborn, DE
• Cornelia Adriana Maria Heinz · Oppenheim, DE
• Christiane Stadler · Bensheim, DE

Key dates

• Filing date: Aug 8, 2016
• Grant date: Jul 17, 2018
• Expiry date: Aug 8, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/734
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.